<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="http://raygent.com/wp-content/plugins/google-sitemap-generator/sitemap.xsl"?><!-- generator="wordpress/3.3.1" -->
<!-- sitemap-generator-url="http://www.arnebrachhold.de" sitemap-generator-version="3.2.6" -->
<!-- generated-on="February 21, 2012 8:29 pm" -->
<!-- Debug: Total comment count: 19 -->
<urlset xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.sitemaps.org/schemas/sitemap/0.9 http://www.sitemaps.org/schemas/sitemap/0.9/sitemap.xsd" xmlns="http://www.sitemaps.org/schemas/sitemap/0.9">	<url>
		<loc>http://raygent.com/</loc>
		<lastmod>2012-02-21T20:29:11+00:00</lastmod>
		<changefreq>daily</changefreq>
		<priority>1.0</priority>
	</url>
<!-- Debug: Start Postings -->
<!-- Debug: Priority report of postID 1578: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biopharm-portfolio/another-daily-reversal-take-more-off-in-biotech/</loc>
		<lastmod>2012-02-21T20:29:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1571: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/gilead-gild-46-50-off-15-on-hep-c-clinical-data-viral-relapse-seen/</loc>
		<lastmod>2012-02-17T19:07:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1566: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biopharm-portfolio/no-panic-just-take-a-little-offcaution/</loc>
		<lastmod>2012-02-16T17:46:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1557: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-racks-up-more-gains-regn-rgdx-srls/</loc>
		<lastmod>2012-02-14T00:34:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1551: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/response-genetics-raises-7-5m-at-1-50-with-new-ceo/</loc>
		<lastmod>2012-02-02T17:53:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1549: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biopharma-market-re-ignited-by-news-and-nasdaq-strength/</loc>
		<lastmod>2012-02-01T20:28:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/buzzwords/</loc>
		<lastmod>2012-02-01T00:22:12+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/buzzwords/</loc>
		<lastmod>2012-02-01T00:19:59+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 1452: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/weather/rayno-snowblog-high-and-dry/</loc>
		<lastmod>2012-01-31T23:49:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1532: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-biopharmaceuticals-portfolio-20909-12712/</loc>
		<lastmod>2012-01-27T19:34:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1522: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-another-buyout-miti-goes-for-1-16b/</loc>
		<lastmod>2012-01-26T14:36:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://raygent.com/contact-us/</loc>
		<lastmod>2012-01-26T14:30:15+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 1507: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/roche-bid-for-illumina-ilmn-drives-biotech-sector-to-new-highs/</loc>
		<lastmod>2012-01-25T20:12:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1501: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/january-effect-traders-take-some-profits/</loc>
		<lastmod>2012-01-23T18:51:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1498: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/january-effect-rolls-on-with-biotech-stocks-up-over-1-9-3-mtd/</loc>
		<lastmod>2012-01-18T20:48:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 644: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/reporting-from-the-jpmorgan-29th-annual-healthcare-conference/</loc>
		<lastmod>2012-01-17T22:50:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1475: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/trends-from-the-jpmorgan-healthcare-conference-2012/</loc>
		<lastmod>2012-01-17T22:37:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1462: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/january-effect-rally-a-cliche-trade-that-really-works/</loc>
		<lastmod>2012-01-12T23:22:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1457: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/jpmorgan-healthcare-conference-life-science-tools-rally/</loc>
		<lastmod>2012-01-11T17:06:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1391: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/caution-on-biotechs-with-risk-off-situation/</loc>
		<lastmod>2012-01-05T16:13:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1431: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/three-small-cap-stocks-for-a-rebound-in-january-amriastxsrls/</loc>
		<lastmod>2012-01-05T16:01:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1440: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotechnology-stock-review-2011/</loc>
		<lastmod>2012-01-02T23:08:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1435: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-diagnostics-and-tools-portfolio-ilmn-neog/</loc>
		<lastmod>2011-12-22T18:13:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1425: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/macro-news-kills-holiday-buzz-markets-off-1-6-and-more/</loc>
		<lastmod>2011-12-08T20:50:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1422: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-tools-rally-a-life-ilmn-qgen/</loc>
		<lastmod>2011-12-05T19:02:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1416: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/pure-play-diagnostics-roster-metrics-with-q3-earnings/</loc>
		<lastmod>2011-12-04T00:39:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1414: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/macro-risk-on-life-science-stock-follow-up-3-4/</loc>
		<lastmod>2011-11-30T20:24:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 882: Comments: 2 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-tools-and-dx-portfolio-update/</loc>
		<lastmod>2011-11-30T00:09:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 876: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-biopharma-portfolioupdate-4411/</loc>
		<lastmod>2011-11-29T23:59:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1404: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biopharm-portfolio/2011-rayno-biopharmaceuticals-portfolio/rayno-life-science-portfolios-run-with-nasdaq-up-3-79/</loc>
		<lastmod>2011-11-29T00:14:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1353: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/mfglobal-where-is-the-customer-money/</loc>
		<lastmod>2011-11-21T19:20:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1394: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/gilead-gild-11b-deal-for-pharmasset-vrus-sparks-biotech-stocks/</loc>
		<lastmod>2011-11-21T19:19:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1260: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/collateral-damage-from-illumina-ilmn-warning-looking-for-new-buys/</loc>
		<lastmod>2011-11-21T19:07:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1383: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biopharm-portfolio/fidelity-biotech-fund-ytd-outperforms-major-etfs/</loc>
		<lastmod>2011-11-16T19:37:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/fidelity-biotech-fund-fbiox-up-7-9-ytd-outperforms-major-etfs/</loc>
		<lastmod>2011-11-16T18:41:48+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/about-us/</loc>
		<lastmod>2011-11-14T02:03:59+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 1361: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biopharm-portfolio/rayno-life-science-portfolio-winners/</loc>
		<lastmod>2011-11-10T22:30:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1349: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/gold-gains-strength-as-fiat-currency-update-1/</loc>
		<lastmod>2011-11-10T22:16:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1364: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/life-science-etfs-and-mutual-funds/rayno-life-science-portfolio-movers/</loc>
		<lastmod>2011-11-09T23:02:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1358: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biopharm-portfolio/bio-investor-forum-october-2011/</loc>
		<lastmod>2011-11-09T22:52:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1346: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/phase-3-malaria-vaccine-trial-effective/</loc>
		<lastmod>2011-11-09T22:38:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1263: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/another-big-rally-on-europe-non-news-biotech-sector-lagging/</loc>
		<lastmod>2011-11-09T22:35:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://raygent.com/archives/</loc>
		<lastmod>2011-11-09T22:14:20+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/rag-real-estate-advisory-group/</loc>
		<lastmod>2011-10-19T00:31:11+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/biopharmaceutical-stock/</loc>
		<lastmod>2011-10-19T00:14:41+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/real-estate-advisory-group-10-09-2005/</loc>
		<lastmod>2011-10-19T00:08:07+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 60: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/tools-portfolio/iuguide-to-biotech-investing/</loc>
		<lastmod>2011-10-10T19:13:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 51: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/innovations-continue-to-drive-market-gains/</loc>
		<lastmod>2011-10-10T18:31:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1256: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/life-science-stocks-rally-into-the-third-day-up-over-2/</loc>
		<lastmod>2011-10-06T20:43:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1253: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/another-wild-day-market-roars-back-in-final-40-minutes/</loc>
		<lastmod>2011-10-04T22:28:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1250: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/sell-off-breaks-through-august-9-technical-bottom-biotechs-weak/</loc>
		<lastmod>2011-10-03T22:23:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1247: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rally-rolls-over-trading-range-intact-biotech-outperforms-in-september/</loc>
		<lastmod>2011-09-27T23:27:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1242: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/life-science-etfs-and-mutual-funds/2009-2010-life-science-portfolio/nasty-day-reminds-us-the-fed-is-running-out-of-juice/</loc>
		<lastmod>2011-09-21T22:09:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1238: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/healthcare-sector-gets-upgrade-from-morgan-stanley/</loc>
		<lastmod>2011-09-16T18:42:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1233: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/life-science-etfs-and-mutual-funds/2009-2010-life-science-portfolio/european-rally-spills-over-to-us-but-life-science-toolsdx-weak/</loc>
		<lastmod>2011-09-15T14:42:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1229: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/life-science-etfs-and-mutual-funds/2009-2010-life-science-portfolio/spontaneous-rally-as-greece-bailout-is-alive-risk-on/</loc>
		<lastmod>2011-09-14T19:36:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 27: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/healthcare-and-biotech-for-relative-safety-alxn-regn-optr-sgen/</loc>
		<lastmod>2011-09-14T05:25:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 16: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/european-debt-esp-greece-drive-market-down-2-8/</loc>
		<lastmod>2011-09-13T22:17:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/</loc>
		<lastmod>2011-09-13T22:07:56+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 1335: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/hello-world-2/</loc>
		<lastmod>2011-09-13T12:06:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1227: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/life-science-etfs-and-mutual-funds/2009-2010-life-science-portfolio/nice-market-turnaround-today-nasdaq-up-1/</loc>
		<lastmod>2011-09-13T03:25:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1224: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/european-debt-esp-greece-drive-markets-down-2-8/</loc>
		<lastmod>2011-09-09T16:48:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1222: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/life-science-etfs-and-mutual-funds/2009-2010-life-science-portfolio/healthcare-and-biotech-for-relative-safety-alxnregnoptrsgen/</loc>
		<lastmod>2011-09-06T21:54:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1219: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/healthcare-and-biotech-stocks-holding-up-well-on-a-bad-day-cbstrgen-sgen/</loc>
		<lastmod>2011-09-02T17:36:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1217: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/life-science-etfs-and-mutual-funds/2009-2010-life-science-portfolio/august-2011-life-science-market-reviewwinners-and-losers/</loc>
		<lastmod>2011-08-31T22:06:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1212: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/stealth-rally-continues-despite-weak-economic-forecasts-life-science-stocks-up-over-2-5/</loc>
		<lastmod>2011-08-29T18:19:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1210: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/stocks-rally-as-fed-shifts-to-idle-biotechs-strong-ilmn-sgen/</loc>
		<lastmod>2011-08-26T18:24:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1207: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/risk-off-day-traders-and-robots-rule/</loc>
		<lastmod>2011-08-25T23:47:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1204: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/three-days-of-market-gains-biotechnology-trades-are-holding/</loc>
		<lastmod>2011-08-24T22:16:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1193: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/global-recession-fears-dominate-market-safety-in-biotechnology-and-large-cap-drugs-stocks/</loc>
		<lastmod>2011-08-22T00:19:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1191: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/sell-off-resumes-as-european-debt-crisis-gets-headlines/</loc>
		<lastmod>2011-08-16T19:42:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1184: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/q2-review-of-pure-play-diagnostic-companiesbargain-hunting-in-abaxgproqgen/</loc>
		<lastmod>2011-08-15T18:53:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1163: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/eurozone-crisis-creates-more-fear-and-a-vicious-sell-off/</loc>
		<lastmod>2011-08-04T17:52:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1161: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/wild-turnaround-day-robotraders-again/</loc>
		<lastmod>2011-08-04T05:14:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1158: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/sell-off-in-the-eighth-day-but-look-to-amgn-and-gpro-for-help/</loc>
		<lastmod>2011-08-02T18:17:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1153: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/debt-deal-healthcare-stocks-sell-off-on-potential-medicare-cuts/</loc>
		<lastmod>2011-08-01T17:37:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1145: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/data-shows-how-dx-companies-are-growing-through-ma/</loc>
		<lastmod>2011-08-01T03:51:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1143: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-tools-and-diagnostics-whats-hot-and-not/</loc>
		<lastmod>2011-07-29T17:26:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1139: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/nice-snapback-rally-in-life-science-today-ilmn-up-3-93-abaxis-abax-leads-up-5/</loc>
		<lastmod>2011-07-28T17:12:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1137: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/illumina-guidance-drags-down-life-science-tools-sector-maintain-caution/</loc>
		<lastmod>2011-07-27T19:04:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1135: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/qqq-still-outperforming-ibb-and-xbi-in-vicious-sell-off/</loc>
		<lastmod>2011-07-27T18:16:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1133: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/qqq-trade-beats-biotech-etfs-after-one-week/</loc>
		<lastmod>2011-07-27T05:03:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1131: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-profit-taking-picks-up-mo-stocks-take-a-hit-caution/</loc>
		<lastmod>2011-07-26T04:07:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1128: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/debt-negotiations-stall-marketgold-up-15-at-1615/</loc>
		<lastmod>2011-07-25T14:32:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1126: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/life-science-etfs-and-mutual-funds/2009-2010-life-science-portfolio/surprise-rally-takes-everything-uptechnology-outperforms-biotechnology/</loc>
		<lastmod>2011-07-20T00:50:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1123: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/life-science-etfs-and-mutual-funds/2009-2010-life-science-portfolio/bulls-better-off-with-qqq-than-pure-biotech-for-now/</loc>
		<lastmod>2011-07-19T17:44:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1119: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/life-science-stocks-in-third-day-of-sell-off/</loc>
		<lastmod>2011-07-18T23:28:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1110: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/review-of-life-science-funds-and-etfs-up-15-ytd/</loc>
		<lastmod>2011-07-16T23:17:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1106: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/sector-watch-energy-on-firetechs-stronghealthcare-a-bit-weak/</loc>
		<lastmod>2011-07-15T20:14:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1102: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/macro-rules-market-qe3-buzz-is-off/</loc>
		<lastmod>2011-07-14T21:37:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1098: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-sciences-portfolio-update-miti-qgen-sgen/</loc>
		<lastmod>2011-07-12T16:48:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1096: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/nyt-article-raises-issues-with-genomics-tests-with-cancer-patients/</loc>
		<lastmod>2011-07-08T16:13:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1093: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-tools-and-dx-big-winners-ytd-cracsiiexasgpro/</loc>
		<lastmod>2011-07-06T20:57:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1089: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/life-science-etfs-and-mutual-funds/2009-2010-life-science-portfolio/rayno-life-science-portfolio-tools-and-dx-immucor-blud-up-30-on-buyout31-5/</loc>
		<lastmod>2011-07-05T13:18:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1083: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-2011-h1-update-biopharm-big-winnersbiib-cbst-regn-sgen/</loc>
		<lastmod>2011-07-05T02:25:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1079: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/trends-from-bio-international-conference-biotech-sector-performance-ytdmtd/</loc>
		<lastmod>2011-06-30T19:47:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1077: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/bio-international-convention-this-week-june-27-30-news-on-amgngild/</loc>
		<lastmod>2011-06-27T03:39:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1075: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/wild-day-on-wall-street-did-the-robotraders-take-over/</loc>
		<lastmod>2011-06-24T00:11:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1073: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/microcaps-revisited-conx-iccc-ivd/</loc>
		<lastmod>2011-06-22T16:55:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1070: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/second-big-rally-day-led-by-materials-technology-and-energy-healthcare-stocks-lag/</loc>
		<lastmod>2011-06-21T22:46:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1068: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-stocks-lead-nasdaq-100-rallybiibcelggild/</loc>
		<lastmod>2011-06-20T18:51:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1064: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/diagnostics-and-tools-updateexasgnmkqgen-rgdx/</loc>
		<lastmod>2011-06-17T18:58:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1062: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/flight-to-safety-with-greek-crisis-some-biotech-winners-sqnmregn/</loc>
		<lastmod>2011-06-15T20:10:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1060: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/relief-rally-boosts-biotechs-biibexelregn/</loc>
		<lastmod>2011-06-14T23:31:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1057: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/post-asco-scoreboard-part-2/</loc>
		<lastmod>2011-06-14T02:53:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1055: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/asco-winners-part-1-ariaecytincy/</loc>
		<lastmod>2011-06-13T23:52:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1051: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/nasty-daynasty-month-nasty-news-cliches-rule/</loc>
		<lastmod>2011-06-10T22:00:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1048: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-stocks-go-green-except-vertex-vrtx/</loc>
		<lastmod>2011-06-09T17:55:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1046: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/june-gloom-continues-asco-buzz-is-off-but-vrus-soars/</loc>
		<lastmod>2011-06-08T19:32:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1042: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/asco-stock-and-news-update-aria-bmy-exel-xbi/</loc>
		<lastmod>2011-06-07T19:12:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1036: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/random-items-celg-investor-network-nflx-ceo-challenges-short-seller/</loc>
		<lastmod>2011-06-06T19:16:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1032: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfoliorisk-is-off-exelgprouthr/</loc>
		<lastmod>2011-06-06T16:04:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1027: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/broad-market-sell-off-after-weak-jobs-data-indices-off-almost-1-at-open/</loc>
		<lastmod>2011-06-03T13:51:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1024: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/new-moon-and-june-gloom-macro-rules-risk-off/</loc>
		<lastmod>2011-06-01T22:06:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1022: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/energytechnology-and-healthcare-sectors-pace-gains-today/</loc>
		<lastmod>2011-05-31T21:41:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1020: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-amri-gild-nktr-optr-all-up/</loc>
		<lastmod>2011-05-31T17:43:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1016: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/stocks-to-watch-asco-continued-incy-onxx-supg/</loc>
		<lastmod>2011-05-27T18:00:17+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1014: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/new-guide-to-biotech-investing-and-etfs/</loc>
		<lastmod>2011-05-27T16:02:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1012: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/stocks-to-watch-asco-presentations-for-ariadndnecyt-and-exel/</loc>
		<lastmod>2011-05-27T04:49:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1009: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/medical-science-news-ramping-up-for-asco/</loc>
		<lastmod>2011-05-25T19:35:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1007: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/personalized-healthcare-gets-a-boost-from-nestleprometheus-deal/</loc>
		<lastmod>2011-05-24T16:47:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1005: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/the-red-screen-is-the-winner-today-but-cubist-cbst-is-up-on-buyout-rumors/</loc>
		<lastmod>2011-05-23T23:11:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1001: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/asco-next-week-rally-today/</loc>
		<lastmod>2011-05-20T19:48:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 998: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-winners-today-abaxcbstcsiineog/</loc>
		<lastmod>2011-05-19T22:16:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 996: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/genprobe-gpro-sells-off-after-thermofisher-tmo-announces-phadia-buyout/</loc>
		<lastmod>2011-05-19T17:06:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 992: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/genprobe-gpro-up-8on-buy-out-rumors/</loc>
		<lastmod>2011-05-18T19:38:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 988: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/metrics-of-pure-play-diagnostic-companies-comparison-to-genprobe/</loc>
		<lastmod>2011-05-18T18:15:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 986: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/big-sell-off-in-oil-gas-and-other-commodities-spooks-the-market/</loc>
		<lastmod>2011-05-11T18:57:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 981: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/life-science-stocks-capture-ma-premium/</loc>
		<lastmod>2011-05-10T18:30:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 974: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/life-science-stocks-are-deal-driven-alkermes-alks-and-elaneln-merge-technologies/</loc>
		<lastmod>2011-05-09T18:58:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 956: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/upbeat-jobs-report-boosts-market-but-rally-fading-biotechs-are-strong/</loc>
		<lastmod>2011-05-06T19:39:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 947: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/reporting-from-the-milken-conference-the-promise-of-medical-science/</loc>
		<lastmod>2011-05-04T18:28:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 952: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/profit-taking-hits-biotechnology-stocks/</loc>
		<lastmod>2011-05-04T17:07:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 941: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/health-and-biotechnology-a-top-performing-sector-ytd-up-13-2/</loc>
		<lastmod>2011-05-03T04:40:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 937: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-diagnostics-and-tools-market-update-genprobe-gproillumina-ilmn-quidel-qdel/</loc>
		<lastmod>2011-04-29T18:23:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 934: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-dx-and-tools-genprobe-gpro-soars-on-for-sale/</loc>
		<lastmod>2011-04-28T17:21:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 928: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-rocks-on-rayno-life-science-portfolio-up-2-2-led-by-regeneron-regn/</loc>
		<lastmod>2011-04-27T21:51:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 921: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-sector-ignited-by-biogen-idec-biib-and-vertex-vrtx/</loc>
		<lastmod>2011-04-26T17:05:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 919: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-market-recap-quiet-day-but-more-red-than-green/</loc>
		<lastmod>2011-04-25T21:32:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 916: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-movers-du-jour-biogen-biib-cubistcbst-nektar-nktr/</loc>
		<lastmod>2011-04-21T16:30:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 912: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/tech-leads-biotech-sector-higher-but-amgen-amgn-and-gilead-gild-weak-after-earnings/</loc>
		<lastmod>2011-04-20T21:46:54+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 909: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/lackluster-trading-in-biotechsell-off-continues-in-smaller-caps/</loc>
		<lastmod>2011-04-19T18:03:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 907: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-rally-ends-with-sbut-amarin-amrn-soars/</loc>
		<lastmod>2011-04-18T19:04:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 905: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-stocks-roll-merrily-along-up-1/</loc>
		<lastmod>2011-04-15T17:32:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 903: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biggest-biotech-trends/</loc>
		<lastmod>2011-04-14T21:10:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 901: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-sector-outperforming-within-nasdaq-dendreondndnidenixidix-and-viropharmavphm-soar/</loc>
		<lastmod>2011-04-14T18:05:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 899: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/life-science-market-update-risk-off-raise-cash/</loc>
		<lastmod>2011-04-12T16:41:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 894: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-exelixis-up-10-pre-market-on-takeover-talk/</loc>
		<lastmod>2011-04-12T13:13:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 891: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-biogen-biib-up-6-6-on-positive-ms-data/</loc>
		<lastmod>2011-04-11T17:36:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 888: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfoliosillumina-ilmn-and-seattle-geneticssgen/</loc>
		<lastmod>2011-04-08T18:33:12+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 884: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/thermofisher-tmo-growth-or-value/</loc>
		<lastmod>2011-04-06T18:55:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 880: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/needham-healthcare-conference-feeds-biotech-rallyalexion-alxn-and-seattle-geneticssgen/</loc>
		<lastmod>2011-04-05T18:22:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 874: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-biopharmaceutical-portfoliocubistcbst-28-40-up-12-on-teva-licensing-deal/</loc>
		<lastmod>2011-04-04T20:52:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 872: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-tools-and-dx-exact-sciences-exas-and-qiagenqgen/</loc>
		<lastmod>2011-04-04T17:31:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 870: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/innovation-drives-market-gains-in-biopharmaceuticals/</loc>
		<lastmod>2011-04-04T16:37:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 865: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/decent-follow-through-from-yesterdays-biotech-rally/</loc>
		<lastmod>2011-03-31T17:36:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 860: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/caution-on-optimer-optr-down-3-in-strong-biotech-market/</loc>
		<lastmod>2011-03-30T20:01:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 857: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-sector-soars-on-valeant-vrx-bid-for-cephalon-ceph/</loc>
		<lastmod>2011-03-30T17:30:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 851: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/rayno-life-science-portfolio-cephalon-ceph-up-27-after-hours-on-valeant-vrx-bid/</loc>
		<lastmod>2011-03-29T21:54:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 848: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-up-1-3-in-a-strong-nasdaq-market/</loc>
		<lastmod>2011-03-29T19:01:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 843: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/technology-convergence-in-medical-technology-abbott-abt-alere-alr-and-merge-mrge/</loc>
		<lastmod>2011-03-29T16:11:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 839: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/ariad-aria-and-molecularmd-collaborate-in-companion-dx-for-cml/</loc>
		<lastmod>2011-03-28T17:26:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 835: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/why-is-the-market-going-up/</loc>
		<lastmod>2011-03-25T17:10:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 833: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/stocks-to-watch-life-science-tools-and-diagnostics-meridianvivo-and-iris/</loc>
		<lastmod>2011-03-24T19:45:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 831: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotechs-bounce-with-good-nasdaq-tape-ariadaria-exelixisexelandoptimeroptr/</loc>
		<lastmod>2011-03-24T17:24:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 825: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/energy-other/nat-gas-is-being-re-discovered-price-up-to-4-35/</loc>
		<lastmod>2011-03-24T04:10:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 822: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-winners-today-despite-xoma-news/</loc>
		<lastmod>2011-03-24T00:16:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 819: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/weather/rayno-snow-blogcan-there-ever-be-too-much-snow-in-the-sierras/</loc>
		<lastmod>2011-03-23T23:46:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 817: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-survivor-xoma-xoma-down-29-on-diabetes-drug-failure-in-mid-stage-study/</loc>
		<lastmod>2011-03-23T16:20:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 815: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-celera-cra-up-29-on-buyout/</loc>
		<lastmod>2011-03-18T14:16:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 811: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/energy-other/nat-gas-rallies-on-nuclear-concernssolid-move-to-4-15/</loc>
		<lastmod>2011-03-17T21:30:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 807: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/cepheidcphd-26-up-3-on-oppenheimer-outperform/</loc>
		<lastmod>2011-03-17T19:10:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 805: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-stocks-down-1-but-winners-up-on-newscardiovascular-systemsosirus-incyte-and-seattle-genetics/</loc>
		<lastmod>2011-03-15T18:51:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 799: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/university-start-ups-all-it-takes-is-money/</loc>
		<lastmod>2011-03-14T18:22:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 802: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/energy-other/nat-gas-over-4-rally-in-a-bear-market/</loc>
		<lastmod>2011-03-14T17:28:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 796: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/weather/raynosnowblog-west-stormy-weather-returning/</loc>
		<lastmod>2011-03-13T22:56:09+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 792: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/healthcare-start-ups-whats-hot/</loc>
		<lastmod>2011-03-11T19:36:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 790: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotechs-sell-off-with-market-but-dendreon-dndn-and-human-genome-are-winnershgsi/</loc>
		<lastmod>2011-03-10T23:09:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 781: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-chronicles-1-the-survivor-business-model/</loc>
		<lastmod>2011-03-09T22:11:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 779: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-update-cubistcbst-and-viropharma-vphm-soar/</loc>
		<lastmod>2011-03-09T17:45:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 777: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rebalancing-sell-the-strong-vertexvrtxbuy-the-weakcephalonceph/</loc>
		<lastmod>2011-03-08T17:59:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 773: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-dx-and-tools-update-caution/</loc>
		<lastmod>2011-03-07T18:35:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 767: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-biopharmaceutical-portfolio-2011-update/</loc>
		<lastmod>2011-03-03T18:18:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 743: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/synthetic-biology-a-new-theme-in-biotechnology/</loc>
		<lastmod>2011-02-24T16:52:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 738: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/energy-other/clean-cheap-nat-gas-who-cares-supply-and-demand-is-predictable/</loc>
		<lastmod>2011-02-24T15:55:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 735: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/nasdaq-down-1-2-to-2723-but-biotech-has-two-big-winnersexelixisexel-and-vertexvrtx/</loc>
		<lastmod>2011-02-23T23:14:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 717: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/good-time-to-look-at-optimer-optr-12-00-pharmaceuticals/</loc>
		<lastmod>2011-02-18T18:46:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 701: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-stocks-get-a-boost-from-the-bio-ceo-conferenceexelixisexeland-optimeroptr/</loc>
		<lastmod>2011-02-14T19:18:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 693: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotechnology-portfolio-notescephivdsrls/</loc>
		<lastmod>2011-02-11T20:28:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 689: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-lifescience-portfolio-sequenomsqnm-news-and-albanymramri-added/</loc>
		<lastmod>2011-02-10T17:46:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 686: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/investors-want-more-from-earningsgenomic-health-ghdxilluminailmn-others/</loc>
		<lastmod>2011-02-09T20:24:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 681: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/weather/rayno-snowblog-west-forecasters-say-we-are-on-the-edge-of-wetness/</loc>
		<lastmod>2011-02-08T19:37:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 677: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/bdbdx-misses-top-line-stock-down-5-to-81-10/</loc>
		<lastmod>2011-02-08T17:11:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 674: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/healthcare-stocks-lagging-the-market-in-2011-but-tools-and-dx-look-better/</loc>
		<lastmod>2011-02-07T20:28:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 672: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/bullish-action-in-biotech-today/</loc>
		<lastmod>2011-01-27T05:12:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 670: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/weather/rayno-snow-blog-lanina-mid-winter-drought/</loc>
		<lastmod>2011-01-26T17:50:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 663: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/amgenamgn-to-buy-biovex-for-cancer-vaccine-technology/</loc>
		<lastmod>2011-01-25T19:00:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 660: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/life-science-news-update700m-in-fed-research-center-at-nih-ad-diagnosis/</loc>
		<lastmod>2011-01-24T18:59:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 656: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-movers-du-jour-clinical-data-clda-and-genoptix-gxdx/</loc>
		<lastmod>2011-01-24T17:14:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 654: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/venture-capital-recovers-biotechnology-gets-3-7b-in-2010/</loc>
		<lastmod>2011-01-21T18:44:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 652: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-2011time-to-raise-a-little-cash/</loc>
		<lastmod>2011-01-21T18:32:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 648: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-stocks-sell-off-on-profit-taking-traders-rule/</loc>
		<lastmod>2011-01-19T22:26:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 637: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-reviewceleracraqiagenqgenand-gileadgild/</loc>
		<lastmod>2011-01-18T15:58:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 635: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/weather/rayno-snow-blog-high-and-dry-in-the-west/</loc>
		<lastmod>2011-01-17T16:59:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 633: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/2011-review-of-rayno-life-science-portfolios-next-week/</loc>
		<lastmod>2011-01-14T19:42:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 630: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/microfluidics-mflu-ob-acquired-for-1-35share/</loc>
		<lastmod>2011-01-11T15:52:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 627: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolios-2011-movers-ardea-rdeaimmucor-blud/</loc>
		<lastmod>2011-01-07T17:13:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1265: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolios-2010-performance/</loc>
		<lastmod>2011-01-06T18:53:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 1264: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/who-knew-land-banks-were-off-balance-sheet/</loc>
		<lastmod>2011-01-05T17:24:14+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 613: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolios-2010-another-excellent-year/</loc>
		<lastmod>2010-12-28T18:59:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 607: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/tis-the-season-of-microcaps-corgenixconb-obimmucell-iccc-and-ivax-ivd/</loc>
		<lastmod>2010-12-27T22:43:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 605: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/vermillion-soars-on-a-quiet-day-vrml-9-up-23-2/</loc>
		<lastmod>2010-12-27T21:20:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 599: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/weather/rayno-snow-blog-la-nina-advisory-and-nat-gas-update-bearish/</loc>
		<lastmod>2010-12-22T19:42:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 594: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/another-good-day-for-biotech-stocksincyteincy-martekmatk-and-xbi/</loc>
		<lastmod>2010-12-21T19:32:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 592: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/reading-list/weekly-news-update-dx-patents-xmrv-avastin-healthcare-reform/</loc>
		<lastmod>2010-12-18T06:11:08+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 588: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-rally-rolls-on-intermune-itmn-up-130/</loc>
		<lastmod>2010-12-17T17:59:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 579: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/healthcare-stocks-come-in-many-flavors-biotech-drugs-life-sciences-medtech/</loc>
		<lastmod>2010-12-16T21:18:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 577: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfoliodx-and-tools-update-121510/</loc>
		<lastmod>2010-12-15T16:35:36+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 574: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/healthcare-stocks-rally-2-on-news-is-sector-rotation-underway/</loc>
		<lastmod>2010-12-14T18:56:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 572: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/weather/rayno-snow-blog-and-nat-gas-update-lanina-on-steroids/</loc>
		<lastmod>2010-12-13T17:43:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 569: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-tools-and-diagnostics-exas-added/</loc>
		<lastmod>2010-12-10T17:33:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 567: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/weather/rayno-snow-blog-nat-gas-sell-off-on-inventory-lanina-advisory/</loc>
		<lastmod>2010-12-09T17:57:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 557: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/play-the-biotech-sector-with-etfs-fbt-ibb-and-xbi/</loc>
		<lastmod>2010-12-06T23:07:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 554: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/weather/rayno-snowblog-lanina-strengthens-nat-gas-gets-weather-boost/</loc>
		<lastmod>2010-12-06T16:46:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 547: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/time-to-buy-drug-stocks-for-yield/</loc>
		<lastmod>2010-12-02T18:27:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 540: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-seracare-srls-surges-11-on-earnings/</loc>
		<lastmod>2010-12-01T19:27:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 538: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/vermillionvrmlnovel-diagnostic-tests-utilizing-biomarkers/</loc>
		<lastmod>2010-11-30T18:44:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 536: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfoliogen-probegpro-files-pma-application-for-hpv/</loc>
		<lastmod>2010-11-30T16:57:49+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 534: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/cepheid-cphd-genexpert-tb-test-in-india/</loc>
		<lastmod>2010-11-30T00:54:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 527: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biomarkers-and-blood-screening-tests-genprobe-gpro-and-genzymegenz/</loc>
		<lastmod>2010-11-26T19:16:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 525: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/market-ignores-bad-news-rallies-on-retail-outlook/</loc>
		<lastmod>2010-11-24T19:53:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 518: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-regeneronregnup-14-on-eye-drug-phase-3-results/</loc>
		<lastmod>2010-11-22T16:58:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 512: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolioexelixis-exel-and-neogen-neog-soar/</loc>
		<lastmod>2010-11-18T19:38:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 510: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/weather/rayno-snowblog-lanina-advisory-incl-nat-gas-trade/</loc>
		<lastmod>2010-11-17T22:21:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 506: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/microfluidics-mflu-ob-revenues-down-9-but-value-play-intact/</loc>
		<lastmod>2010-11-17T19:02:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 504: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-update-bludilmn-neogsqnm/</loc>
		<lastmod>2010-11-08T18:57:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 500: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/cardiovascular-systems-csii-gains-traction-good-value-play/</loc>
		<lastmod>2010-11-05T17:33:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 498: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/raynolifescience-portfolio-earnings-update-abaxgpro/</loc>
		<lastmod>2010-10-29T18:58:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 494: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/exact-sciences-exas-reports-positive-data-for-colorectal-cancer-test/</loc>
		<lastmod>2010-10-28T17:40:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 484: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/great-day-for-biotech-toolsearnings-up-and-pacbio-pacb-ipo/</loc>
		<lastmod>2010-10-27T17:14:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 478: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/ge-healthcare-buys-oncology-diagnostic-co-clarient-clrt/</loc>
		<lastmod>2010-10-22T17:12:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 476: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-big-movers-gilead-gildsupergen-supg/</loc>
		<lastmod>2010-10-20T18:21:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 473: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-notes-q3-earnings-in-two-weeks/</loc>
		<lastmod>2010-10-15T18:55:07+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 469: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/immucor-blud-cuts-guidance-blames-economy/</loc>
		<lastmod>2010-10-06T22:00:18+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 465: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-tools-and-dx/</loc>
		<lastmod>2010-10-05T17:58:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 458: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/2010-life-science-portfolio-update-biopharma/</loc>
		<lastmod>2010-10-04T23:03:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 455: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-update-biotechs-beat-the-market/</loc>
		<lastmod>2010-09-30T03:55:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 451: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/stealth-stock-rally-catches-bears-off-guarddont-fight-the-tape/</loc>
		<lastmod>2010-09-24T17:20:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 443: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rodmanrenshaw-part-2rosetta-genomicsrosgand-response-geneticsrgdx/</loc>
		<lastmod>2010-09-23T23:26:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 439: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rodmanrenshaw-notes-part-2-sequenom-sqnm/</loc>
		<lastmod>2010-09-21T22:11:52+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 437: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/energy-other/sierra-snowblog-2010-la-nina-pattern-next-3-months-cold-for-northern-u-s/</loc>
		<lastmod>2010-09-21T17:59:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 435: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rodmanrenshaw-notes-part-2-adeonaenand-exact-sciencesexas/</loc>
		<lastmod>2010-09-20T19:02:50+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 430: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/notes-from-the-rodmanrenshaw-global-investment-conference-part1/</loc>
		<lastmod>2010-09-16T15:20:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 426: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/reading-list/stem-cell-debate-and-the-courts/</loc>
		<lastmod>2010-09-09T23:11:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 423: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/zymogenetics-zgen-buyout-boost-biotech-stocks/</loc>
		<lastmod>2010-09-08T17:33:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 420: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-rides-the-september-1-rally-with-a-2-5-move-up/</loc>
		<lastmod>2010-09-01T19:23:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 416: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/good-riddance-to-august-2010-part-2-safe-havens-in-biotech-and-gold/</loc>
		<lastmod>2010-08-31T19:01:53+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 414: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/good-riddance-to-august-2010-part-1-bonds-for-everyman/</loc>
		<lastmod>2010-08-31T18:20:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 410: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/life-science-etfs-and-mutual-funds/2009-2010-life-science-portfolio/macro-and-trading-rules-risk-remains-off/</loc>
		<lastmod>2010-08-26T23:18:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 404: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/successful-ipos-in-genomics-could-ignite-biotech-stocks/</loc>
		<lastmod>2010-08-18T04:48:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 402: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/microfluidicsmflu-0b-update-reiterate-buy-at-0-85/</loc>
		<lastmod>2010-08-12T22:02:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 400: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/summer-rally-is-over-risk-is-off/</loc>
		<lastmod>2010-08-11T17:57:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 394: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/after-the-fed-value-found-in-global-pharma-stocks/</loc>
		<lastmod>2010-08-10T19:28:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 392: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/life-science-tools-and-dx-calipercalp-and-celera-crareport-results/</loc>
		<lastmod>2010-08-04T17:27:25+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 386: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/model-portfoliolife-science-tools-and-dx/</loc>
		<lastmod>2010-08-03T20:56:56+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 384: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/aacc-notes-biomarkers-for-cardiovascular-risk-hscrp/</loc>
		<lastmod>2010-08-03T17:47:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 381: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/novartisnvs-and-pathwork-dx-collaborate-on-biomarkers/</loc>
		<lastmod>2010-08-02T18:18:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 377: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/aacc-effect-rally-rolls-on-abaxisabaxgenprobe-gproand-quidel-qdel/</loc>
		<lastmod>2010-07-30T15:13:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 370: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/aacc-notes-diagnostic-stocks-and-rayno-model-portfolio/</loc>
		<lastmod>2010-07-29T19:21:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 364: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/aacc-meeting-buzz-coming-to-fuel-the-rally-in-diagnostic-stocks/</loc>
		<lastmod>2010-07-26T16:13:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 356: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/big-movers-in-diagnostics-today-immucor-blud-up-6-5-and-cepheid-cphd-up-12/</loc>
		<lastmod>2010-07-23T20:19:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 354: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/gilead-holding-up-at-33-on-exhaustion-of-negativity/</loc>
		<lastmod>2010-07-21T18:49:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 347: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/q2-earnings-reports-gilead-gild-and-meridian-vivo/</loc>
		<lastmod>2010-07-20T22:01:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 345: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/funding-of-technology-start-ups-and-campus-incubators/</loc>
		<lastmod>2010-07-08T17:26:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 343: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/news-update-hospital-costs-can-go-up-as-a-result-of-bad-trades/</loc>
		<lastmod>2010-07-08T16:41:31+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 331: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biomarker-diagnostics-drive-personalized-medicine/</loc>
		<lastmod>2010-07-06T17:19:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 326: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/auxilium-auxl-holding-up-after-barrons-not-so-great-math/</loc>
		<lastmod>2010-06-28T19:15:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 324: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/oncology-pipeline-update/</loc>
		<lastmod>2010-06-28T17:54:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 322: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/supergensupg-in-a-rally-mode-at-2-43reiterate-buy/</loc>
		<lastmod>2010-06-25T16:34:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 320: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/post-asco-doldrums/</loc>
		<lastmod>2010-06-24T19:34:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 317: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/multinational-drug-stocks-and-the-euro-etffxe/</loc>
		<lastmod>2010-06-15T22:14:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 313: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/genomics-boom-boosts-sales-of-research-tools/</loc>
		<lastmod>2010-06-14T17:24:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 311: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-update-finally-a-rally-day/</loc>
		<lastmod>2010-06-10T21:37:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 309: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/asco-little-help-for-biotech-stocks/</loc>
		<lastmod>2010-06-07T22:39:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 307: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/cubist-cbst-pharmaceuticals-up-3-on-heavy-volume/</loc>
		<lastmod>2010-06-04T18:10:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 298: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/genetic-testing-gets-a-boost-from-medcomhs/</loc>
		<lastmod>2010-05-19T21:51:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 294: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/pathway-genomics-makes-giant-marketing-step-in-personalized-medoicine/</loc>
		<lastmod>2010-05-12T17:01:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 292: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/response-geneticsrgdx-signs-agreement-with-glaxo-for-braf-gene/</loc>
		<lastmod>2010-05-11T16:22:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 285: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/biomarkers-drive-personalized-medicine/</loc>
		<lastmod>2010-05-10T15:33:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 269: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/dendreondndn-receives-fda-approval-for-therapeutic-cancer-vaccine/</loc>
		<lastmod>2010-04-29T21:39:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 266: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/milken-institute-global-conference-healthcare-reform-i/</loc>
		<lastmod>2010-04-27T18:48:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 262: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/gileadgild-and-abbottabt-guidance-triggers-biotech-sell-off/</loc>
		<lastmod>2010-04-21T17:21:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 260: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/genomics-update-from-aacr-biomarkers-for-oncology-medicine/</loc>
		<lastmod>2010-04-20T22:48:19+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 258: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/helicoshlcs-update/</loc>
		<lastmod>2010-04-19T17:18:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 254: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/genomics-update-biomarkers-help-select-personalized-oncology-medicine/</loc>
		<lastmod>2010-04-19T16:28:44+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 251: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/goldman-charge-curbs-enthusiasm-for-market-risk/</loc>
		<lastmod>2010-04-16T17:33:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 246: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-2010-biopharmaceuticals/</loc>
		<lastmod>2010-04-15T17:49:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 232: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-life-science-portfolio-diagnostics-and-tools-14-mos-ytd/</loc>
		<lastmod>2010-04-05T19:39:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 239: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/immucorblud-profits-up-but-stock-down-8/</loc>
		<lastmod>2010-04-01T17:43:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 235: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/gene-patent-ruling-stalls-biotech-rally-myriad-mygn-down-4-9/</loc>
		<lastmod>2010-03-30T19:41:30+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 230: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/market-reversal-today-be-cautious/</loc>
		<lastmod>2010-03-25T22:08:01+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 228: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/2009-2010-life-sciences-portfolio/</loc>
		<lastmod>2010-03-23T17:56:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 226: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/healthcare-stocks-up-market-absorbs-reform/</loc>
		<lastmod>2010-03-22T17:59:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 224: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/2010-life-science-portfolio-look-at-immucor-blud/</loc>
		<lastmod>2010-03-18T18:46:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 222: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/sequenom-sqnm-catching-bids-at-5-75/</loc>
		<lastmod>2010-03-18T17:18:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 215: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/whats-next-for-helicoshlcs/</loc>
		<lastmod>2010-03-15T16:32:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 211: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/intermuneitmn-up-60-on-panel-go-ahead/</loc>
		<lastmod>2010-03-09T22:31:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 207: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/why-healthcare-reform-is-so-difficult/</loc>
		<lastmod>2010-03-09T17:45:21+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 204: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-mojo-risin-with-intermune-surge/</loc>
		<lastmod>2010-03-05T17:22:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 202: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/medivation-hangover-stock-stable/</loc>
		<lastmod>2010-03-04T19:06:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 200: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/medivation-chills-biotech-sector/</loc>
		<lastmod>2010-03-03T16:56:27+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 198: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/microfluidics-mflu-ob-update-turnaround-intact/</loc>
		<lastmod>2010-02-24T17:46:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 193: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/clinical-diagnostics-part-2-market-sector-poised-for-growth/</loc>
		<lastmod>2010-02-17T19:59:41+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 191: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/clinical-diagnostics-part-1-a-sector-poised-for-growth/</loc>
		<lastmod>2010-02-16T19:57:38+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 189: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/complete-genomics/</loc>
		<lastmod>2010-02-15T19:20:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 187: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/isis-and-genz-meet-trial-goal-isis-stock-sells-off/</loc>
		<lastmod>2010-02-10T18:14:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 185: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/new-coverage-genomics-and-diagnostics-genomic-healthghdx/</loc>
		<lastmod>2010-02-09T19:53:03+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 183: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/microfluidics-mflu-ob-0-90-a-leader-in-advanced-nano-material-processing-for-a-variety-of-industries/</loc>
		<lastmod>2010-02-05T19:56:46+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 177: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/life-science-sector-performance-etfs-and-funds-feb-12-mosytd/</loc>
		<lastmod>2010-01-29T21:23:34+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 175: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biomedical-stocks-beat-the-bleak/</loc>
		<lastmod>2010-01-28T22:51:57+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 173: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/gilead-sciences-revenues-and-profits-up-sharply-on-antiviral-drugs/</loc>
		<lastmod>2010-01-27T00:55:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 171: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/amgen-earnings-just-ok-january-effect-for-bio-topped-out/</loc>
		<lastmod>2010-01-25T22:08:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 169: Comments: 1 of 19 = 0.1 points -->
	<url>
		<loc>http://raygent.com/biograph/waxman-power-play-to-squeeze-biotech-for-biogenerics/</loc>
		<lastmod>2010-01-15T19:16:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 167: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/jpmorgan-healthcare-conference-2010-themes-and-news/</loc>
		<lastmod>2010-01-15T16:21:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 165: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/jpmorgan-healthcare-conference-2010-day-one-monday-january-11/</loc>
		<lastmod>2010-01-12T18:57:35+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 163: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/jpmorgan-healthcare-conference-jan11-14-san-francisco/</loc>
		<lastmod>2010-01-08T18:51:39+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 161: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/volcanovolc-erupts-9-on-upgrade/</loc>
		<lastmod>2010-01-04T19:39:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 158: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/review-of-biotech-2009-fund-and-etf-performance-ytd/</loc>
		<lastmod>2009-12-30T20:28:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 156: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/compugencgen-deal-sparks-small-cap-biodiscovery-stocks/</loc>
		<lastmod>2009-12-23T18:36:20+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 154: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/year-end-biotech-rally-on-schedule/</loc>
		<lastmod>2009-12-21T18:59:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 151: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/sequenom-down-75-on-xenomics-power-play/</loc>
		<lastmod>2009-12-17T23:31:40+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 149: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/h1n1-boosts-development-in-pharma-sector/</loc>
		<lastmod>2009-12-01T19:20:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 146: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/positioning-for-a-possible-year-end-biotech-rally/</loc>
		<lastmod>2009-11-19T04:07:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 144: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-stock-rally-continues-mid-caps-up-25/</loc>
		<lastmod>2009-11-16T20:30:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 141: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-sell-off-abating/</loc>
		<lastmod>2009-11-04T19:29:00+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 139: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-sell-off-continues-2/</loc>
		<lastmod>2009-10-23T17:03:48+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 137: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-stocks-in-stealth-retreat/</loc>
		<lastmod>2009-10-21T04:04:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 135: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/life-science-market-performance-q3-2009/</loc>
		<lastmod>2009-10-07T14:28:32+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 131: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/h1n1-swine-flu-activity-picks-up-vaccine-roll-out-underway/</loc>
		<lastmod>2009-10-02T22:11:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 129: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/markets-stable-after-sell-offdollar-down/</loc>
		<lastmod>2009-10-02T18:58:28+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 127: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/energy-other/caution-flag-up-with-broad-sell-off-of-2-3-deflation-risk-back/</loc>
		<lastmod>2009-10-02T00:35:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 125: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/gold-up-17-to-974-gold-and-silver-stocks-follow/</loc>
		<lastmod>2009-09-02T17:08:58+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 123: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/reflation-trade-back-on-crude-updollar-down-housing-sales-up/</loc>
		<lastmod>2009-08-21T17:33:45+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 121: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/h1n1-influenza-vaccine-manufacturers-ramp-up-for-october-15/</loc>
		<lastmod>2009-08-20T15:07:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 119: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/risk-trade-off-with-strong-dollar-weak-china-action/</loc>
		<lastmod>2009-08-17T19:51:15+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 117: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/biotech-sell-off-continues/</loc>
		<lastmod>2009-08-14T18:46:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 115: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/caution-on-biotechs-and-energy/</loc>
		<lastmod>2009-08-07T04:53:02+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 113: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/weak-dollar-boosts-reflation-trade/</loc>
		<lastmod>2009-07-31T17:29:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 109: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/medarex-acquisition-ignites-broad-biotech-rally/</loc>
		<lastmod>2009-07-24T15:51:47+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 107: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rally-updateenergy-and-metals-lead-the-way/</loc>
		<lastmod>2009-07-17T18:31:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 105: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/broad-market-move-up-2-reflation-trade-back/</loc>
		<lastmod>2009-07-13T22:23:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 103: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/rayno-2009-biotechnology-portfolio-mid-year-update/</loc>
		<lastmod>2009-07-13T18:46:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 101: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/reflation-trade-kicks-back-stay-cautious/</loc>
		<lastmod>2009-07-03T19:43:22+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 99: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/reflation-trade-turns-cautious-3-market-sell-off/</loc>
		<lastmod>2009-06-22T21:40:11+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 97: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/h1n1-flu-pandemic-is-here-but-moderate-in-severity/</loc>
		<lastmod>2009-06-15T03:15:37+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 94: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/ten-year-treasury-auction-drives-yield-to-399/</loc>
		<lastmod>2009-06-10T21:35:51+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 91: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/reflation-trade-picks-up-after-auction/</loc>
		<lastmod>2009-05-27T18:28:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 87: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/perfect-storm-of-financial-distress-from-bio/</loc>
		<lastmod>2009-05-21T23:34:43+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 85: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/update-on-biomarkers-from-bio-conf/</loc>
		<lastmod>2009-05-21T23:30:13+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 81: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/reflation-trade-kicks-up/</loc>
		<lastmod>2009-05-04T21:34:05+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/lockdown-mode-paralyzes-bioindustry/</loc>
		<lastmod>2009-05-02T00:19:51+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 80: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/swine-flu-fear-boost-biotechs/</loc>
		<lastmod>2009-04-27T18:51:06+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 79: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/macro-reflation-trade-deflation-risk-persists/</loc>
		<lastmod>2009-04-14T23:15:26+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 78: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/q1-biotechnology-update/</loc>
		<lastmod>2009-04-13T15:15:42+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 77: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/reflation-trade-print-print-print-to-fight-deflation/</loc>
		<lastmod>2009-03-18T19:18:10+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 76: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/big-rally-in-biopharm-coming-off-technical-bottoms/</loc>
		<lastmod>2009-03-13T05:28:29+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 75: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/blockbuster-mergers-fail-to-lift-biotech-stocks/</loc>
		<lastmod>2009-03-09T10:06:04+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 74: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/risk-appetite-fades-reflation-ebbing-feb252009/</loc>
		<lastmod>2009-02-25T19:40:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 73: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/macro-reflation-trade-update-from-dec-16-2008/</loc>
		<lastmod>2009-02-03T10:51:55+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/2009-biopharmaceutical-portfolio/</loc>
		<lastmod>2009-02-03T01:18:31+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: Priority report of postID 1334: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/macro-reflation/macro-reflationdeflation-update-feb-112009/</loc>
		<lastmod>2009-02-02T19:24:33+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 72: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/jpmorgan-healthcare-conference2/</loc>
		<lastmod>2009-01-16T18:53:23+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 71: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/other/rag/2005-real-estate-post-from-patricknet/</loc>
		<lastmod>2009-01-16T18:52:24+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 70: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/jpmorgan-healthcare-conference/</loc>
		<lastmod>2009-01-15T18:45:59+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
<!-- Debug: Priority report of postID 69: Comments: 0 of 19 = 0 points -->
	<url>
		<loc>http://raygent.com/biograph/raygent-biopharmaceutical-stock-portfolio-beats-the-market-for-2008/</loc>
		<lastmod>2009-01-05T18:55:16+00:00</lastmod>
		<changefreq>monthly</changefreq>
		<priority>0.2</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/waxman/</loc>
		<lastmod>2008-12-06T01:16:07+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/alzheimers-disease/</loc>
		<lastmod>2008-09-02T23:27:24+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/new-genetic-tests-play-stronger-role-in-targeting-therapy-part-ii/</loc>
		<lastmod>2008-09-02T23:21:07+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/recession-fears-trumped-by-higher-crude-and-supply-disruptions/</loc>
		<lastmod>2008-02-12T00:43:26+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/2008-gen-wall-street-roundup/</loc>
		<lastmod>2008-01-10T00:43:02+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/biotech-gen-august-2007/</loc>
		<lastmod>2007-07-02T23:46:38+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/2007-energy-blog/</loc>
		<lastmod>2007-07-02T23:44:44+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/cancer-vaccines/</loc>
		<lastmod>2007-02-06T00:48:43+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/biotechnology-2007/</loc>
		<lastmod>2007-02-02T00:47:44+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/molecular-dx/</loc>
		<lastmod>2006-09-02T00:01:45+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/emerging-biopharmaceutical/</loc>
		<lastmod>2006-04-02T00:59:23+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/investing-in-healthcare/</loc>
		<lastmod>2006-01-17T01:02:49+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/rag-2005/</loc>
		<lastmod>2005-09-29T07:00:00+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/diabetes/</loc>
		<lastmod>2005-09-13T00:04:29+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/american-society-of-clinical-oncology-2005/</loc>
		<lastmod>2005-05-24T00:12:00+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
	<url>
		<loc>http://raygent.com/articles/investing-in-biotechnology/</loc>
		<lastmod>2004-11-04T01:13:19+00:00</lastmod>
		<changefreq>weekly</changefreq>
		<priority>0.6</priority>
	</url>
<!-- Debug: End Postings -->
<!-- Debug: Start Custom Pages -->
<!-- Debug: End Custom Pages -->
<!-- Debug: Start additional URLs -->
<!-- Debug: End additional URLs -->
</urlset>
